High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism

Q Medicine

Clinical Lipidology Pub Date : 2015-02-01 DOI:10.2217/clp.14.64

J. Robert, Wai Hang Cheng, Arooj Hayat, Taylor Ward-Able, C. Wellington

引用次数: 4

Abstract

Abstract The brain is the most lipid-rich organ in the body and contains 25% of the body’s total cholesterol content. ApoE is the major apolipoprotein expressed in the brain and genetic variations in apoE underlie much of the genetically determined risk of late-onset Alzheimer’s disease. Regulation of lipid homeostasis in the CNS is therefore of great interest for healthy brain aging. The brain’s lipid transport system is built around lipoprotein particles that are similar in size and presumed function to circulating HDL. It is increasingly appreciated that many comorbidities that increase Alzheimer’s disease risk include aspects of aberrant HDL-metabolism, yet how circulating HDL may impact brain health is not fully understood. As comprehending the similarities and differences between CNS and peripheral lipid metabolism may reveal important relationships between cardiovascular and neurological diseases, here we review the fundamental properties of HDL metabolism in both peripheral and CNS compartments.

查看原文本刊更多论文

高密度脂蛋白在中枢神经系统和血浆脂蛋白代谢之间的界面

大脑是体内脂质最丰富的器官，其胆固醇含量占全身总胆固醇含量的25%。载脂蛋白e是大脑中表达的主要载脂蛋白，载脂蛋白e的遗传变异在很大程度上决定了晚发型阿尔茨海默病的遗传风险。因此，中枢神经系统脂质稳态的调节对健康的大脑衰老具有重要意义。大脑的脂质转运系统是围绕脂蛋白颗粒构建的，它们的大小和功能与循环中的高密度脂蛋白相似。人们越来越认识到，许多增加阿尔茨海默病风险的合并症包括HDL代谢异常的方面，但循环HDL如何影响大脑健康尚未完全了解。由于了解中枢神经系统和外周脂质代谢的异同可能揭示心血管和神经疾病之间的重要关系，我们在这里综述了外周和中枢神经系统中HDL代谢的基本特性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.